AstraZeneca pulls French Brilique reimbursement filing

25 March 2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said it has withdrawn a reimbursement application for its potentially blockbuster blood thinner Brilique (ticagrelor, also using the brand name Brilinta for the USA) in France after an advisory agency requested more information about the drug’s medical benefit.

The company plans to re-file for a pricing decision along with the requested data in the coming months on the drug, which was approved by European regulatory authorities at the end of last year (The Pharma Letter December 6, 2010) but is still held up at the US Food and Drug Administration.

French preference for Plavix and aspirin combination?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >